Name | Betahistine dihydrochloride |
Description | Betahistine dihydrochloride (Betahistine 2HCl) is a histamine analog and H1 receptor agonist that serves as a vasodilator. |
In vitro | In mice, Betahistine (ED50=2 mg/kg) elevates t-MeHA levels in a dose-dependent manner. In patients with Ménière's disease, Betahistine (16 mg, twice daily for 3 months) significantly alleviates vertigo. Additionally, Betahistine (50 mg/kg) induces an upregulation of histidine decarboxylase mRNA in the nodose ganglion of the cat brain. |
In vivo | In CHO(H3R) cells treated with 3 μM of, Betahistine progressively increased cAMP formation, peaking at 10 nM. Furthermore, in CHO(H3R) cells, Betahistine progressively reduced A23187-induced [3H]arachidonic acid release (EC50=0.1 nM), with the greatest effect observed at 30 nM. |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (239.1 mM) H2O : 35 mg/mL (167.4 mM) Ethanol : 1 mg/mL (4.78 mM)
|
Keywords | PT9 | arthritis | antipsychotic | Rheumatoid | inhibit | Betahistine Dihydrochloride | Histamine Receptor | schizophrenia | episode | Betahistine dihydrochloride | Ménière | CIA | Inhibitor | Betahistine | PT 9 | disease |
Inhibitors Related | Chlorphenesin | Meclizine dihydrochloride | Mirtazapine | Lidocaine | Famotidine | Mebhydrolin napadisylate | Amitriptyline hydrochloride | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |